PE20211453A1 - Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina - Google Patents
Formulacion liofilizada de un anticuerpo monoclonal contra transtirretinaInfo
- Publication number
- PE20211453A1 PE20211453A1 PE2020000653A PE2020000653A PE20211453A1 PE 20211453 A1 PE20211453 A1 PE 20211453A1 PE 2020000653 A PE2020000653 A PE 2020000653A PE 2020000653 A PE2020000653 A PE 2020000653A PE 20211453 A1 PE20211453 A1 PE 20211453A1
- Authority
- PE
- Peru
- Prior art keywords
- present
- monoclonal antibody
- cdrs
- seq
- concentration
- Prior art date
Links
- 239000012931 lyophilized formulation Substances 0.000 title 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000009697 arginine Nutrition 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000008362 succinate buffer Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592294P | 2017-11-29 | 2017-11-29 | |
| PCT/US2018/062902 WO2019108689A1 (en) | 2017-11-29 | 2018-11-28 | Lyophilized formulation of a monoclonal antibody against transthyretin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211453A1 true PE20211453A1 (es) | 2021-08-05 |
Family
ID=66665773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000653A PE20211453A1 (es) | 2017-11-29 | 2018-11-28 | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11873332B2 (enExample) |
| EP (1) | EP3717512A4 (enExample) |
| JP (1) | JP7337057B2 (enExample) |
| KR (1) | KR20200090164A (enExample) |
| CN (1) | CN111433223B (enExample) |
| AU (1) | AU2018375356A1 (enExample) |
| BR (1) | BR112020010483A2 (enExample) |
| CA (1) | CA3083356A1 (enExample) |
| CL (1) | CL2020001391A1 (enExample) |
| CU (1) | CU20200042A7 (enExample) |
| EA (1) | EA202091130A1 (enExample) |
| IL (1) | IL274958A (enExample) |
| JO (1) | JOP20200132A1 (enExample) |
| MA (1) | MA51223A (enExample) |
| MX (1) | MX2020005433A (enExample) |
| PE (1) | PE20211453A1 (enExample) |
| PH (1) | PH12020550694A1 (enExample) |
| SG (1) | SG11202004187UA (enExample) |
| WO (1) | WO2019108689A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| MX2020003043A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Métodos para detectar transtiretina. |
| CN111433223B (zh) | 2017-11-29 | 2024-08-27 | 诺和诺德A/S（股份有限公司） | 抗甲状腺素运载蛋白单克隆抗体的冻干制剂 |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| JP2023525790A (ja) * | 2020-05-12 | 2023-06-19 | ニューリミューン エイジー | Ｔｔｒアミロイドーシスに対する併用療法 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| JP2023548005A (ja) * | 2020-10-28 | 2023-11-15 | ノヴォ ノルディスク アー／エス | 抗トランスサイレチン抗体およびその使用方法 |
| CN113845593B (zh) * | 2021-10-27 | 2023-03-10 | 福州迈新生物技术开发有限公司 | 抗α-SMA蛋白单克隆抗体、细胞系及其应用 |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| JP2025537803A (ja) | 2022-11-15 | 2025-11-20 | ニューリミューン アーゲー | トランスサイレチン媒介性アミロイドーシスを治療又は予防するための医薬組成物 |
| EP4619431A1 (en) | 2022-11-15 | 2025-09-24 | Neurimmune AG | Methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2024123791A1 (en) * | 2022-12-05 | 2024-06-13 | Kodiak Sciences Inc. | Formulations for dual vegf/il-6 inhibitors |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| TW202528347A (zh) * | 2023-11-15 | 2025-07-16 | 瑞士商紐立慕公司 | 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法 |
| TW202525341A (zh) | 2023-12-15 | 2025-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | 穩定的液體調配物 |
| WO2025238147A1 (en) | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| BR0007956A (pt) | 1999-02-05 | 2002-04-09 | Samsung Electronics Co Ltd | Método de recuperação de textura por imagem e equipamento para essa finalidade, e meio legìvel por computador |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| CA2404237C (en) | 2000-04-05 | 2010-01-26 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
| EP1578361B1 (en) | 2002-09-12 | 2011-04-20 | The Regents of The University of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
| US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
| JP4344325B2 (ja) | 2002-11-29 | 2009-10-14 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法 |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| AU2004272112A1 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| KR101235658B1 (ko) | 2004-11-10 | 2013-02-21 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | Ｃｈｏ 세포에 대한 세포 뱅킹 전략을 최적화하기 위한 유동 세포측정 분석의 용도 |
| WO2006108234A1 (en) | 2005-04-13 | 2006-10-19 | Garvan Institute Of Medical Research | Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor |
| JP5823663B2 (ja) | 2006-03-03 | 2015-11-25 | プロミス ニューロサイエンシズ インコーポレイテッド | ミスフォールドｓｏｄ１媒介疾患を処置および検出するための方法および組成物 |
| WO2008005455A2 (en) | 2006-07-03 | 2008-01-10 | The Johns Hopkins University | Peptide antibody depletion and its application to mass spectrometry sample preparation |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| EP2078189B1 (en) | 2006-10-20 | 2012-10-10 | Clondiag GmbH | Assay devices and methods for the detection of analytes |
| KR20100015363A (ko) | 2007-03-02 | 2010-02-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 단백질 생산의 개선 |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| DK2342220T3 (da) | 2008-10-06 | 2021-08-09 | Univ British Columbia | Metoder og systemer til forudsigelse af misfoldede proteinepitoper |
| JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| WO2010099612A1 (en) | 2009-03-02 | 2010-09-10 | The University Of British Columbia | Antibodies and epitopes specific to misfolded prion protein |
| WO2011116123A1 (en) | 2010-03-19 | 2011-09-22 | Irm Llc | Tafamidis for the treatment of ophthalmic diseases |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP2560942B1 (en) | 2010-04-21 | 2014-11-26 | Chiesi Farmaceutici S.p.A. | 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis |
| JP5896175B2 (ja) | 2010-04-29 | 2016-03-30 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | トランスサイレチン発現の調節 |
| FI20115165A0 (fi) | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| AU2012233313C1 (en) | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| EP2857419B1 (en) | 2012-05-30 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US9534048B2 (en) | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| PL2995680T3 (pl) | 2013-03-12 | 2019-06-28 | National University Corporation Nagoya University | Sposób zwiększania fotosyntezy i wydajności plonu roślin |
| US20160168235A1 (en) | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| SG11201604831QA (en) | 2013-12-20 | 2016-08-30 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor |
| PT3101132T (pt) | 2014-01-29 | 2021-12-31 | Km Biologics Co Ltd | Anticorpo humano anti-transtirretina |
| CN106574258B (zh) | 2014-01-29 | 2021-03-30 | Km生物医药股份公司 | 抗-运甲状腺素蛋白人源化抗体 |
| EP3185957B1 (en) | 2014-08-29 | 2022-06-01 | Alnylam Pharmaceuticals, Inc. | Patisiran for use in treating transthyretin mediated amyloidosis |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI711631B (zh) | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| EP3478714A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CN107389956B (zh) * | 2017-08-31 | 2019-05-07 | 北京臻惠康生物科技有限公司 | 甲状腺素运载蛋白作为tbi患者受伤严重程度评估的新用途及其试剂盒 |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| MX2020003043A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Métodos para detectar transtiretina. |
| CN111433223B (zh) | 2017-11-29 | 2024-08-27 | 诺和诺德A/S（股份有限公司） | 抗甲状腺素运载蛋白单克隆抗体的冻干制剂 |
| WO2021168156A1 (en) | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
-
2018
- 2018-11-28 CN CN201880076019.0A patent/CN111433223B/zh active Active
- 2018-11-28 MX MX2020005433A patent/MX2020005433A/es unknown
- 2018-11-28 CU CU2020000042A patent/CU20200042A7/es unknown
- 2018-11-28 BR BR112020010483-3A patent/BR112020010483A2/pt not_active IP Right Cessation
- 2018-11-28 EP EP18882542.6A patent/EP3717512A4/en active Pending
- 2018-11-28 WO PCT/US2018/062902 patent/WO2019108689A1/en not_active Ceased
- 2018-11-28 EA EA202091130A patent/EA202091130A1/ru unknown
- 2018-11-28 MA MA051223A patent/MA51223A/fr unknown
- 2018-11-28 CA CA3083356A patent/CA3083356A1/en active Pending
- 2018-11-28 JP JP2020528890A patent/JP7337057B2/ja active Active
- 2018-11-28 KR KR1020207015129A patent/KR20200090164A/ko not_active Ceased
- 2018-11-28 SG SG11202004187UA patent/SG11202004187UA/en unknown
- 2018-11-28 PH PH1/2020/550694A patent/PH12020550694A1/en unknown
- 2018-11-28 JO JOP/2020/0132A patent/JOP20200132A1/ar unknown
- 2018-11-28 PE PE2020000653A patent/PE20211453A1/es unknown
- 2018-11-28 AU AU2018375356A patent/AU2018375356A1/en not_active Abandoned
- 2018-11-28 US US16/767,994 patent/US11873332B2/en active Active
-
2020
- 2020-05-26 IL IL274958A patent/IL274958A/en unknown
- 2020-05-27 CL CL2020001391A patent/CL2020001391A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202004187UA (en) | 2020-06-29 |
| US20200362023A1 (en) | 2020-11-19 |
| PH12020550694A1 (en) | 2021-04-12 |
| MX2020005433A (es) | 2020-08-27 |
| CU20200042A7 (es) | 2021-03-11 |
| IL274958A (en) | 2020-07-30 |
| JOP20200132A1 (ar) | 2022-10-30 |
| CN111433223A (zh) | 2020-07-17 |
| CA3083356A1 (en) | 2019-06-06 |
| KR20200090164A (ko) | 2020-07-28 |
| EP3717512A4 (en) | 2021-08-25 |
| EP3717512A1 (en) | 2020-10-07 |
| JP7337057B2 (ja) | 2023-09-01 |
| EA202091130A1 (ru) | 2020-08-28 |
| CN111433223B (zh) | 2024-08-27 |
| MA51223A (fr) | 2020-10-07 |
| US11873332B2 (en) | 2024-01-16 |
| JP2021504372A (ja) | 2021-02-15 |
| CL2020001391A1 (es) | 2020-11-13 |
| AU2018375356A1 (en) | 2020-05-14 |
| WO2019108689A1 (en) | 2019-06-06 |
| BR112020010483A2 (pt) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211453A1 (es) | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina | |
| TWI419705B (zh) | 抗ｐｄ－ｌ１抗體及其於增進ｔ細胞功能之用途 | |
| RU2019100887A (ru) | Композиции антитела и белка | |
| SI2331090T1 (en) | Stable liquid antibody formulation | |
| PE20201503A1 (es) | Formulaciones de inmunoconjugado anti-cd79b estables | |
| PE20200513A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| RU2013148537A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| RU2019100221A (ru) | Составы на основе антитела к CD19 | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| JP2016533335A5 (enExample) | ||
| RU2015111319A (ru) | Препараты антитела к рецептору анти-пролактина | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| RU2012131099A (ru) | Препарат антитела | |
| JP2020158505A5 (enExample) | ||
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| IL272773B2 (en) | Pharmaceutical preparations containing anti-amyloid cell antibodies | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| CL2024000232A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| PE20221281A1 (es) | Formulaciones de anticuerpos anti-pd-l1 | |
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| EA201591108A1 (ru) | Слитый гормон роста человека и альбумин, составы и их применения | |
| AR107774A1 (es) | Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer |